{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:04:09Z","timestamp":1791489849325,"version":"4.3.4"},"reference-count":11,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Intravenous alemtuzumab is an effective and well-tolerated treatment for T-cell prolymphocytic leukemia (T-PLL). Alemtuzumab given intravenously as first-line treatment in 32 patients resulted in an overall response rate of 91% with 81% complete responses. Studies in B-cell chronic lymphocytic leukemia have shown subcutaneous alemtuzumab to be equally as effective as intravenous alemtuzumab. The UKCLL05 pilot study examined the efficacy and toxicity of this more convenient method of administration in 9 previously untreated patients with T-PLL. Only 3 of 9 patients (33%) responded to treatment. Furthermore, 2 of 9 patients (22%) died while on treatment. Recruitment was terminated because of these poor results. After rescue therapy with intravenous alemtuzumab and\/or pentostatin, median progression-free survival and overall survival were similar to the intravenous group. Alemtuzumab delivered intravenously, but not subcutaneously, remains the treatment of choice for previously untreated T-PLL. This study is registered at www.eudract.ema.europa.eu as #2004-004636-31.<\/jats:p>","DOI":"10.1182\/blood-2011-08-372854","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T03:51:41Z","timestamp":1317095501000},"page":"5799-5802","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":89,"title":["Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route"],"prefix":"10.1182","volume":"118","author":[{"given":"Claire E.","family":"Dearden","sequence":"first","affiliation":[{"name":"The Royal Marsden National Health Service (NHS) Trust, Sutton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khot","sequence":"additional","affiliation":[{"name":"The Royal Marsden National Health Service (NHS) Trust, Sutton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Else","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, Sutton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Hamblin","sequence":"additional","affiliation":[{"name":"Colchester General Hospital, Essex, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie","family":"Grand","sequence":"additional","affiliation":[{"name":"Salisbury District Hospital, Wiltshire, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Roy","sequence":"additional","affiliation":[{"name":"Basingstoke and North Hampshire NHS Foundation Trust, Hampshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Hewamana","sequence":"additional","affiliation":[{"name":"The Royal Marsden National Health Service (NHS) Trust, Sutton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estella","family":"Matutes","sequence":"additional","affiliation":[{"name":"The Royal Marsden National Health Service (NHS) Trust, Sutton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Catovsky","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, Sutton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111807284308200_B1","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia.","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"issue":"7","key":"2019111807284308200_B2","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","article-title":"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.","volume":"15","author":"Pawson","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807284308200_B3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with Campath-1H.","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111807284308200_B4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","article-title":"Campath- 1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.","volume":"20","author":"Keating","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807284308200_B5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2130.2130","article-title":"TPLL-1 protocol of the German CLL Study Group (GCLLSG): a prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL [abstract].","volume":"110","author":"Hopfinger","year":"2007","journal-title":"Blood"},{"issue":"32","key":"2019111807284308200_B6","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807284308200_B7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2141.2010.08134.x","article-title":"Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.","volume":"149","author":"Krishnan","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111807284308200_B8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti\u2013CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"issue":"24","key":"2019111807284308200_B9","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807284308200_B10","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111807284308200_B11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3324\/haematol.2010.033159","article-title":"Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.","volume":"96","author":"Montagna","year":"2011","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/22\/5799\/1345174\/zh804811005799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/22\/5799\/1345174\/zh804811005799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:36:13Z","timestamp":1574080573000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/22\/5799\/29147\/Alemtuzumab-therapy-in-Tcell-prolymphocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,24]]},"references-count":11,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2011,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-08-372854","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,24]]}}}